SCHEMBL17742954

SCHEMBL17742954

Cc1ccccc1S(=O)(=O)NC1=C(Cl)C(=O)c2ccccc2C1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.55
HTT P42858 7/20 0.55
KMT2A Q03164 6/20 0.55
MAPK1 P28482 4/20 0.55
NPSR1 Q6W5P4 4/20 0.55
ALDH1A1 P00352 6/20 0.53
LMNA P02545 5/20 0.53
MEN1 O00255 4/20 0.53
HPGD P15428 2/20 0.53
KDM4E B2RXH2 1/20 0.53
RAB9A P51151 4/20 0.53
MITF O75030 3/20 0.53
NPC1 O15118 3/20 0.53
TDP1 Q9NUW8 3/20 0.51
POLB P06746 2/20 0.51
USP2 O75604 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
RXFP1 Q9HBX9 1/20 0.51
GAA P10253 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19625588 0.80 MAPT (0.68) MAPTHTTKMT2AMAPK1NPSR1
SCHEMBL17742930 0.80 NAT1 (0.68) MAPTHTTKMT2AMAPK1NPSR1
SCHEMBL17739600 0.79 MAPT (0.52) MAPTHTTKMT2AMAPK1NPSR1
SCHEMBL1815994 0.79 MAPT (0.71) MAPTHTTKMT2AMAPK1NPSR1
SCHEMBL16297011 0.77 KMT2A (0.67) MAPTHTTKMT2AMAPK1NPSR1
SCHEMBL19625586 0.77 MAPT (0.50) MAPTHTTKMT2AMAPK1NPSR1
SCHEMBL19628325 0.76 CYP1A2 (0.42) MAPTKMT2AMAPK1ALDH1A1LMNA
SCHEMBL5806361 0.74 MAPT (0.64) MAPTHTTKMT2AMAPK1NPSR1
SCHEMBL16297166 0.74 MAPT (0.57) MAPTHTTKMT2AMAPK1NPSR1
SCHEMBL16297045 0.74 KMT2A (0.68) MAPTHTTKMT2AMAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170334842-A1 INHIBITORS OF THE MITF MOLECULAR PATHWAY UNIVERSITY OF KANSAS 2017-11-23 US disclosed
US-9745261-B2 Inhibitors of the MITF molecular pathway THE GENERAL HOSPITAL CORPORATION (US) 2017-08-29 US disclosed
US-20160130222-A1 INHIBITORS OF THE MITF MOLECULAR PATHWAY THE BROAD INSTITUTE, INC. 2016-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160130222-A1 INHIBITORS OF THE MITF MOLECULAR PATHWAY MITF, TFEB, TYR MAPT 4100/4885HTT 1337/4885KMT2A 2018/4885
US-20170334842-A1 INHIBITORS OF THE MITF MOLECULAR PATHWAY MITF, TFEB, TYR MAPT 4092/4885HTT 1443/4885KMT2A 2146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.